NEUMORA THERAPEUTICS, INC. Other Income and Expense
NEUMORA THERAPEUTICS, INC. (NMRA) reported Other Income and Expense of -$892.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2026-06-30 was -$892.00K, a 166.87% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2026-03-31 was -$564.00K, a 118.50% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2025-12-31 was -$970.00K, a 123.64% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2025-09-30 was $945.00K, a 77.24% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2025 was $4.36M, a 78.05% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2024 was $19.86M, a 20.77% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2023 was $16.44M, a 231.07% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2022 was $4.97M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$892.00K 10-Q · filed 2026-08-14 | -$1.46M 10-Q · filed 2026-08-14 | -$2.43M derived: sum of 3 quarters · filed 2026-08-14 | -$1.48M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$564.00K 10-Q · filed 2026-05-07 | -$1.53M derived: sum of 2 quarters · filed 2026-05-07 | -$589.00K derived: sum of 3 quarters · filed 2026-05-07 | $745.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$25.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.31M derived: sum of 3 quarters · filed 2026-08-14 | $4.36M 10-K · filed 2026-03-30 |
| 2025-09-30 | $945.00K 10-Q · filed 2025-11-06 | $2.28M derived: sum of 2 quarters · filed 2026-08-14 | $5.33M 10-Q · filed 2025-11-06 | $9.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.33M 10-Q · filed 2026-08-14 | $4.38M 10-Q · filed 2026-08-14 | $8.49M derived: sum of 3 quarters · filed 2026-08-14 | $12.64M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.05M 10-Q · filed 2026-05-07 | $7.15M derived: sum of 2 quarters · filed 2026-05-07 | $11.30M derived: sum of 3 quarters · filed 2026-05-07 | $16.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.26M derived: sum of 2 quarters · filed 2026-03-30 | $13.50M derived: sum of 3 quarters · filed 2026-03-30 | $19.86M 10-K · filed 2026-03-30 |
| 2024-09-30 | $4.15M 10-Q · filed 2025-11-06 | $9.40M derived: sum of 2 quarters · filed 2025-11-06 | $15.75M 10-Q · filed 2025-11-06 | $21.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.25M 10-Q · filed 2025-08-06 | $11.60M 10-Q · filed 2025-08-06 | $17.14M derived: sum of 3 quarters · filed 2025-08-06 | $20.98M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $6.35M 10-Q · filed 2025-05-12 | $11.89M derived: sum of 2 quarters · filed 2025-05-12 | $15.73M derived: sum of 3 quarters · filed 2025-05-12 | $19.25M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $9.38M derived: sum of 2 quarters · filed 2025-03-03 | $12.90M derived: sum of 3 quarters · filed 2025-03-03 | $16.44M 10-K · filed 2025-03-03 |
| 2023-09-30 | $3.84M 10-Q · filed 2024-11-12 | $7.36M derived: sum of 2 quarters · filed 2024-11-12 | $10.90M 10-Q · filed 2024-11-12 | $13.47M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $3.52M 10-Q · filed 2024-08-06 | $7.06M 10-Q · filed 2024-08-06 | $9.63M derived: sum of 3 quarters · filed 2025-03-03 | $10.89M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $3.54M 10-Q · filed 2024-05-07 | $6.12M derived: sum of 2 quarters · filed 2025-03-03 | $7.37M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $3.83M derived: sum of 2 quarters · filed 2025-03-03 | $4.97M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $1.26M 10-Q · filed 2023-11-01 | $2.39M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |